Analysts Set Kenvue Inc. (NYSE:KVUE) Price Target at $19.58

Kenvue Inc. (NYSE:KVUE) has been given an average recommendation of “Hold” by the sixteen research firms that are covering the firm, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $19.5833.

Several equities research analysts have commented on KVUE shares. UBS Group boosted their price objective on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, July 16th. Citigroup dropped their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. Wall Street Zen upgraded Kenvue to a “buy” rating in a report on Sunday, July 12th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Finally, Barclays increased their target price on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday.

Kenvue Stock Performance

NYSE:KVUE opened at $19.25 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The stock has a market capitalization of $36.97 billion, a PE ratio of 22.65, a P/E/G ratio of 1.46 and a beta of 0.47. Kenvue has a fifty-two week low of $14.02 and a fifty-two week high of $22.87. The company has a fifty day moving average of $18.38 and a two-hundred day moving average of $17.92.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the previous year, the company earned $0.24 earnings per share. The company’s quarterly revenue was up 4.5% on a year-over-year basis. As a group, research analysts forecast that Kenvue will post 1.16 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Insider Buying and Selling at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.59% of the stock is currently owned by corporate insiders.

Institutional Trading of Kenvue

Several large investors have recently added to or reduced their stakes in KVUE. Merit Financial Group LLC boosted its holdings in Kenvue by 15.7% in the 2nd quarter. Merit Financial Group LLC now owns 77,208 shares of the company’s stock valued at $1,475,000 after purchasing an additional 10,483 shares during the last quarter. Corecam AG purchased a new position in Kenvue in the second quarter worth approximately $344,000. Rosenberg Matthew Hamilton increased its stake in Kenvue by 341.9% during the second quarter. Rosenberg Matthew Hamilton now owns 3,045 shares of the company’s stock worth $58,000 after acquiring an additional 2,356 shares during the last quarter. Farther Finance Advisors LLC raised its position in Kenvue by 6.5% in the second quarter. Farther Finance Advisors LLC now owns 68,743 shares of the company’s stock valued at $1,314,000 after purchasing an additional 4,184 shares during the period. Finally, Ballentine Partners LLC lifted its stake in shares of Kenvue by 6.0% in the 2nd quarter. Ballentine Partners LLC now owns 18,477 shares of the company’s stock valued at $353,000 after purchasing an additional 1,052 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.